Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.

Cancer medicine - 1 May 2026

Spriano Filippo, Cascione Luciano, Tarantelli Chiara, Sartori Giulio, Arribas Alberto J, Velasova Adriana, Napoli Sara, Havranek Ondrej, Toretsky Jeffrey A, Bertoni Francesco

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) remains a challenging disease with limited therapeutic options beyond standard immunochemotherapy. ETS transcription factors, including SPIB and SPI1, are implicated in lymphoma pathogenesis and can be targeted by the small molecule TK216, which disrupts ETS-DHX9 interactions. To explore mechanisms of resistance, we generated stable TK216-resistant clones from the ABC-DLBCL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Drug Screening Assays, Antitumor

Share to G2 Phase Cell Cycle Checkpoints

Share to Gene Expression Regulation, Neoplastic

Share to Lymphoma, Large B-Cell, Diffuse

Share to Proto-Oncogene Proteins c-ets

Source

Open in PubMed Open full text

Identifiers

PMID: 42130064
DOI: 10.1002/cam4.71935
PMCID: PMC13172266

Genes

ABCB1
BCL2
DHX9
ESR2
MCL1
PATJ
SFSWAP
SPI1
SPIB
SRSF11
USP24
XPO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.PMID 42130064Read ↗

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistanceSemantic proximity Read ↗

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.Semantic proximity Read ↗

Drug therapy for double-hit lymphomaSemantic proximity Read ↗

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.Semantic proximity Read ↗

Establishment and characterization of 18 Sarcoma Cell Lines: Unraveling the Molecular Mechanisms of Doxorubicin Resistance in Sarcoma Cell Lines.Semantic proximity Read ↗

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesSemantic proximity Read ↗

Drug Resistance in Non-Hodgkin LymphomasSemantic proximity Read ↗

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphomaSemantic proximity Read ↗

Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATRSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.